Dare Bioscience (DARE) Change in Receivables (2016 - 2024)

Dare Bioscience's (DARE) quarterly Change in Receivables came in at -$39665.0 in Q2 2024, down 158.64% on a QoQ basis from $67644.0 in Q1 2024.

Dare Bioscience (DARE) Change in Receivables (2016 - 2024) Analysis & Trends

Dare Bioscience (DARE) has 3 years of Change in Receivables data on file, last reported at -$39665.0 in Q2 2024.

Quarterly Change in Receivables changed N/A year-over-year to -$39665.0 in Q2 2024, while the trailing twelve-month figure through Jun 2025 was $27979.0 (changed 0.0% YoY) and the FY2025 annual result came in at $12053.0, changed N/A from the prior year.
Change in Receivables fell to -$39665.0 in Q2 2024, from $67644.0 in the prior quarter.
In the past five years, Change in Receivables ranged from a high of $67644.0 in Q1 2024 to a low of -$39665.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-53.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	117.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	31.60 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	94.29 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	37.16 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Dare Bioscience	12.36 Mn	-256,055.23	-132,343.00	-

Download Data